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approach. A truncated CD36 cDNA was constructed that encodes a protein that terminates just proximal to the putative C-terminal transmembrane domain. This mutant was cloned into eukaryotic expression plasmid vectors to generate short-term and stable transfected cells. Our results indicate that the truncated mutant is secreted by the transfectants into the postculture medium, indicating that there is only one transmembrane domain in CD36, which is present at the C-terminal end. The soluble secreted protein from all of these cells is functional as indicated by its binding to thrombospondin.
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platelet CD36 begins at the residue immediately after the initiator methionine, it is probable that this signal sequence remains part of the mature molecule. Recently, a rat lysosomal integral membrane protein I1 (LIMP 11) with greater than 60% sequence homology to CD36 has been identified and cloned. It too has a nonprocessed signal peptide that has been shown to function as a second transmembrane domain.*'j By analogy, Greenwalt et a l ' have hypothesized that CD36 also has two transmembrane and two intracellular domains.
Understanding the transmembrane domains of CD36 is important because of studies suggesting that the intracytoplasmic domains of CD36 are functionally active. For example, CD36 can mediate uptake and internalization of ligands (such as oxidized LDLZ4 and apoptotic neutrophils2'). Presumably internalization signals are carried in its intracellular domain(s). In addition, Aiken et a1" have shown that certain monoclonal anti-CD36 antibodies can activate platelets, while our lab and others have shown that monocytes can be activated by monoclonal and polyclonal anti-CD36 IgG.29 Huang et a13' have shown that platelet CD36 associates intracellularly with 3 nonreceptor protein tyrosine kinases of the src family: fyn, lyn, and yes. We have confirmed this with both platelets and peripheral blood monocytes. Presumably, engagement of CD36 might activate these kinases and therefore initiate a signal transduction cascade leading to cellular activation. Understanding the molecular details of the intracellular domain(s) of CD36 is thus critical in understanding how CD36 engagement may transduce cellular signals. We report here data with deletion mutagenesis showing that CD36 has only a single C-terminal transmembrane domain, and that a functional truncated CD36 lacking this domain is secreted into the postculture medium (PCM) by transfected cells.
MATERIALS AND METHODS
Preparation of the CD36 truncation mutant. A CD36 cDNA fragment consisting of bp I through 1,727 was removed from plasmid pCDMWCD36 (kindly provided by Dr Brian Seed, Massachusetts General Hospital, Boston, MA) by Xba I digestion and subcloned into pUC18 plasmid. A fragment from bp 1,495 through 1,605 was then removed by Nsp l digestion. The plasmid was recirBlood, VOI 84, NO 2 (July 15). 1994: pp 384-389 use only.
For personal at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From cularized and then the truncated insert was removed and cloned directionally into EcoRI and HindIII sites in two plasmid expression vectors, pCMV5 and pMV7. The 3' end of the cloned cDNAs were verified by mapping and direct nucleotide sequencing. These plasmids have been described e l~e w h e r e~'~'~ as excellent high level eukaryotic expression vectors for transient COS cell transfections and stable neomycin-resistant transfections, respectively. The truncation mutant encodes a protein that lacks the C-terminal 43 amino acids of native CD36, including the intracytoplasmic and transmembrane domains. The mutant proteins include an additional short carboxy terminal stretch encoded by the remaining sequences in the original 5' untranslated region. These are GLENNKISMYQKILLQ. Transfection was performed using cationic lipid (Lipofectin reagent; GIBCO BRL Scientific, Grand Island, NY). Briefly, 100-mm tissue culture plates containing 30% to 50% confluent cells in serum-free media were treated with dropwise addition of 10 to 15 pg of DNA mixed with 30 pL of lipofectin reagent in 500 pL sterile water. Normal growth media containing serum was added to the cells after 24 hours of DNA incubation. Transient COS7 cell transfectants were harvested after 48 hours. Stable Bowes melanoma cell and Chinese hamster ovary (CHO) cell transfectants were selected by adding media containing G418 (250 to 300 pg/mL) 48 hours after transfection. Thereafter cells were kept in G418 at all times. RNase protection assays3' were performed to verify high levels of CD36 mRNA expression in all transfected cell cultures. Stable transfectants were used experimentally approximately 6 weeks after transfection.
Iodination of TSP, transfected cells, and PCM. TSP, transfected cells, and concentrated PCM were labeled with '2s[I] NaI using immobilized chloramine T (IODOBEAD; Pierce Chemical CO, Rockford, IL), as previously de~cribed.'~ The PCM were concentrated using centricon concentrators, (Amicon, Beverly, MA) to a volume of 1 mL.
Immunoprecipitation of the CD36 mutant. '"[I] surface-labeled cells were lysed for 60 minutes at 4°C in 1 mL of lysis buffer (25 mmol/L Tris, 144 m m o E NaCl, 1.0 mmol/L phenylmethylsulfonyl fluoride [PMSF], 2 mmoVL EDTA, 1% NP-40, 20 pglmL aprotinin, pH 7.4). The lysate was centrifuged at 3,OOOg for 10 minutes to remove nuclei and insoluble intracellular material. These lysates and concentrated PCM were precleared twice with 20 pL Pansorbin cells (Calbiochem, La Jolla, CA) and were incubated with either anti-CD36 8A6 IgG or nonimmune mouse IgG for 2 hours at 4°C. They were then precipitated with rabbit antimouse IgG linked to Pansorbin. In some studies, the PCM was precipitated with a rabbit antibody raised against a synthetic 10 amino acid peptide corresponding to the N-terminus of bovine CD36 (GCNRNCGLIY-COOH) crosslinked to bovine serum albumin (BSA), generously provided by Dr Dale Greenwalt (American Red Cross, Rockville Center, MD). The resulting complexes were washed three times with a high stringency lysis buffer (150 mmol/L NaCI, 1.0% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS] , 50 mmol/L Tris, pH 7.4) and analyzed by 10% or 8% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
Puri$cation of recombinant CD36 from PCM. Secreted truncated CD36 in the PCM from stably transfected cells was purified using a procedure previously described for platelet CD36,34,35 ie, sequential ion-exchange chromatography on Q-sepharose and wheat germ agglutinin chromatography. The purified protein was characterized by Western blot with rabbit polyclonal and mouse monoclonal anti-CD36 IgG (FA6-152 obtained from the Vth International Workshop on Leukocyte Differentiation Antigens, Boston, MA), as well as by immunoprecipitation of the ''SII]-labeled purified material with monoclonal 8A6 anti-CD36.
Metabolic labeling of cells. CH0 and Bowes melanoma cells stably transfected with pMV7 containing the CD36 truncation mutant were grown to 50% to 70% confluence. The medium was removed and the cells were incubated in methionine-and cysteine-free medium (EMEM media; ICN Biochemicals, Imine, CA) for 30 minutes. Fresh methionine-and cysteine-free media containing 1 mCi of "[SImethionine and 35[S]-cysteine (ICN Radiochemicals) was then added to the cells. After overnight incubation, cells and PCM were harvested and immunoprecipitated with 8A6 anti-CD36 as described above.
Binding assays. Solid-phase binding assays were used to quantify TSP interactions with full-length CD36 and truncated CD36 proteins produced by the transfected cells. Murine monoclonal anti-CD36 (5F1), which does not block TSP binding, was immobilized at 2 pg/mL on wells in a detachable 96-microwell plate by overnight incubation at 4°C. Cell lysates or PCM diluted in 20 mmolL Tris, 150 mmol/L NaCl, pH 7.4, containing 0.05% Tween-20 (TBSTween) were overlayered on the plates and incubated for 3 hours. After washing three times, wells were blocked with TBS-Tween containing 0.5% BSA. Labeled ''s[I]-TSP was then added in TBSTween containing 1 mmol/L CaCl, and the mixture was incubated for 3 hours at 37°C. The wells were then washed thoroughly and dried, and bound radioactivity was quantified by gamma counter. Nonspecific binding was determined by performing the binding in the presence of 5 mmol/L EDTA or excess unlabeled ligand and was generally less than 10% of total.
RESULTS AND DISCUSSION
Based on hydropathy analysis and sequence homology to LIMPII, CD36 has been postulated to contain two transmembrane regions, one at the C-terminal end and the other at the N-terminal end. Because the truncation mutant we created does not contain the C-terminal transmembrane region, we expect that if there are two transmembrane domains the mutant protein would remain membrane attached via the Nterminal end. However, if there is only one transmembrane region at the C-terminus, then we expect the protein to be secreted into the PCM. Wild-type COS cells or COS cells transfected with either pCDM8 containing the entire CD36 construct or with pCMV5 containing the C-terminal truncation mutant were examined for surface expression of CD36 by indirect immunofluorescence flow cytometry. No significant surface expression could be detected in the cells transfected with the mutant using several anti-CD36 monoclonal antibodies. RNase protection assays3' using a 600-bp fragment from the 5' end of the intact CD36 cDNA showed similar abundant levels of CD36 mRNA in both the fulllength and the truncated cDNA transfectants. To determine whether the lack of surface expression was caused by secretion or by problems with translation of the mutant mRNA, we analyzed cell membranes, total cells lysates, and PCM by immunoprecipitation with a specific anti-CD36 monoclonal antibody, 8A6. A portion of the labeled cells was also washed with Na2C03 to remove any surface adhered protein.
No proteins were precipitated from PCM of cells transfected with the full-length cDNA or from cell surfaces of cells transfected with the truncation mutant. However, intact CD36 (88 kD) was precipitated from surface-labeled cells transfected with full-length cDNA (Fig lA, lane 4) , whereas a truncated CD36 (78 kD) was immunoprecipitated from the PCM of the cells transfected with the mutant (lane 3). No proteins were specifically precipitated by nonimmune con- trol IgGs (lanes 2 and 5 ) or from the Na2C03 wash (lane 1). These data demonstrate that the truncation mutant was secreted into the PCM and was not surface expressed.
To produce larger quantities of truncated CD36 and to demonstrate that secretion was not unique to COS cells, two other cell lines (CH0 and Bowes human melanoma cells) were transfected with the same cDNA inserted into a plasmid expression vector driven by a retroviral LTR promotor and carrying the neomycin-resistance gene. Stable cell lines expressing the CD36 truncation mutant were produced, and truncated CD36 was purified from PCM using a method applied previously for intact platelet CD36.34.35 Immunoprecipitations of the purified proteins with anti-CD36 8A6 IgG were performed after labeling the protein with '*'[I]-NaI. Control cells expressing intact CD36 were simultaneously surface labeled with "'[I]-NaI and the protein immunoprecipitated from cell lysates. As seen in Fig IB, surface-labeled CD36 (88 kD) was precipitated only from C H 0 and Bowes cells transfected with the intact CD36 cDNA, whereas a 78-kD protein was precipitated only from the PCM of cells transfected with the truncation mutant. Similar data were obtained from metabolically labeled cells and PCM (data not shown). To verify that the truncated protein was secreted and not present in PCM from release of cell membrane fragments or by cell lysis, the PCM was centrifuged both at low speed (3,0008) to remove cell debris and at high speed (100,OOOg) to remove membrane fragments. More than 90% of the truncated mutant was found in the soluble fraction, confirming that the mutant was indeed secreted. In addition, immunocytofluorescence microscopy and Western blots (data not shown) showed only trace amounts of cell-associated CD36 in the mutant transfectants compared with cells transfected with the intact CD36 cDNA. Because cell viability assays indicated that greater than 99.8% of the transfected cells excluded trypan blue, cell lysis is an unlikely explanation for the presence of CD36 in the PCM. To verify that the secreted truncated CD36 contained the complete N-terminal hydrophobic domain, we demonstrated reactivity with a rabbit antiserum raised against a synthetic I O amino acid peptide derived from the N-terminal sequence of bovine CD36. As seen in Fig 2, intact human platelet CD36 was specifically precipitated by this serum, indicating that the N-terminus of human CD36 could be recognized by this antibody. Immunoprecipitation of the purified truncation mutant with this serum showed a band at 78 kD that is similar to the protein precipitated from the PCM shown in Fig 1. This interaction was blocked with excess unlabeled platelet CD36 or unlabeled truncation mutant, but not by excess BSA (Fig 2) , demonstrating specificity. Thus, the secreted protein includes the N-terminal I O amino acid domain.
The secreted truncated protein was also examined for TSP binding properties because the putative TSP binding regions were not removed by the truncation." From previous studies it was found that COS'' and C H 0 cells (unpublished data) transfected with a plasmid containing the intact CD36 cDNA did not bind TSP, whereas the Bowes melanoma cells similarly transfected bound TSP.37 Using a monoclonal antibody capture and binding assay we found that "'[I]-TSP bound specifically to intact CD36 immunoadsorbed from lysates of use only. ble. with an apparent dissociation constant similar to that seen with intact platelet CD36 or recombinant CD36 immunoadsorbed from lysed Bowcs cell transfectants. In all of these studies. equivalent amounts of CD36 was adsorbed to the wells under each set of conditions as assessed by enzymelinked immunosorbent assay with a second anti-CD36 monoclonal antibody reactive with a different epitope than SFI. 
